December 19, 2010

The Bottom Line: Idexx passes the test

Growing markets for quick, accurate ways to test for animal diseases, and for contaminants in water and milk, drive the health of a Westbrook company.

By J. Hemmerdinger
Staff Writer

(Continued from page 1)

click image to enlarge

Vanessa Vigue, a scientific research associate, performs a test at Idexx Laboratories in Westbrook.

Gordon Chibroski/Staff Photographer

click image to enlarge

Idexx’s SNAP tests have multiple dotted test strips for determining animal diseases.

Gordon Chibroski/Staff Photographer



HISTORY: Idexx was founded in 1983 by David Shaw, now a partner at the Portland-based investment firm Black Point Group. The company launched with diagnostic kits and computerized monitoring systems for poultry, cattle and swine producers. Soon, Idexx entered the so-called companion animal industry, selling products that test dogs and cats. Today, the company sells products to 50,000 veterinary clinics worldwide and every year makes some 26 million SNAP tests, a product that lets vets quickly check pets for heartworm, Lyme disease and other illnesses. Idexx also sells products that test for contaminants in water and milk.

EMPLOYEES: 4,700, including 1,600 in Westbrook

CEO: Jonathan Ayers


Since Ayers took the helm in 2002, Idexx revenue nearly tripled from $386 million to more than $1 billion, and the number of staff in Maine has doubled to 1,600.

Nearly 40 percent of the company’s revenues come from international sales, in 168 countries.

Idexx has manufacturing plants in Maine, Georgia, the United Kingdom, France and Switzerland.

FINANCIALS: Idexx reported revenue of $1.03 billion in 2009, nearly the same as in 2008. The company expects 2010 revenue to be $1.1 billion.

STOCK: IDXX. Trading around $70 per share.

Brock said Idexx has a "phenomenal leadership team" that has boosted efficiency by reducing the number of parts that go into machines, minimizing the number of vendors and improving the supply chain.

The popular SNAP tests are made by the Companion Animal Group, which had revenue of $843 million in 2009 and sells tests to some 50,000 veterinary clinics worldwide. This group's VetLab products include a variety of blood-analyzing machines, including ProCyte Dx, which gives a complete white and red blood cell analysis in just minutes.

"It's faster than your family doctor," Ayers said. "If you take your dog in for a checkup, the doctor has got (the results) during the visit and can look at them with you."

The animal group also sells the VetLab Station, an information management system that integrates test results into a single report. And for more detailed lab work, veterinarians can send samples to Idexx's laboratories.

Brock said the animal group's range of products gives Idexx an advantage. "They have a diversified operating portfolio. They have created multiple touch points with vets."

Another Idexx division, the Livestock and Poultry Diagnostics group, made $77 million last year selling products detecting disease in poultry, swine and cattle.

And the $73 million Water division sells water contamination tests in 35 countries.

A local Idexx customer is the Portland Water District, which supplies drinking water to Portland and surrounding towns.

Peter Rush, an environmental scientist with the water district, said the district tests water samples for coliform bacteria and E. coli bacteria with an Idexx powder called Colilert.

"If the sample remains clear, it passes. If it turns yellow it is positive," he said.

Portland Water District also checks saltwater at swimming beaches for bacteria with Idexx's Enterolent.

Rush said the water district has bought Idexx products for many years and worked with the company during product testing.

He said Idexx products are expensive but easier to use and less prone to error than earlier tests.

"We've been having a really good working relationship with them," he said.

Another Idexx division, the Dairy group, makes milk-testing products.

Ayers said an effort by this division in 2008 demonstrates the company's innovation and agility. That year, a deadly contaminant called melamine, used to enhance apparent food protein levels, was found in baby formula in China. Several children died.

Ayers said Idexx staff in China and Maine rushed to find a solution, and within just seven months -- a remarkably short development period -- released the SNAP Melamine Test Kit, which rapidly detects contamination in milk used to make baby formula.

Successes aside, Ayers said the recession was hard on Idexx. Revenue, which had grown for years, flattened between 2008 and 2009, but has since resumed climbing.

A restructuring in the last few years resulted in some lost jobs (just 1 percent or 2 percent of the work force, Ayers said), but overall the company has added employees in recent years.

Idexx had planned to build a $50 million headquarters building in Five Star Industrial Park and hire 500 new staff, but the expansion was stalled by a plan by Pike Industries to blast a rock quarry in the park.

Idexx reached an agreement with Pike and the city of Westbrook, but the expansion remains in flux, partly due to economic concerns, said Dick Daigle, Idexx facilities manager.

A few months ago, however, the company began building a new $5 million mezzanine to accommodate Idexx's growth. Daigle said the addition will be able to house 130 people.

In the next seven or eight years, Ayers expects the company to grow worldwide, perhaps doubling in size.

"With that will come more jobs. I'm not sure how many, (but) plans are for growth around the world," he said.

Brock, the Kaufman analyst, also expects more good things out of Idexx. She said the stock has been "on fire" in the last couple weeks, despite an uncertain economy, and she expects Idexx to capture more market share.

"Even when GPD goes flat to negative, these guys are growing," she said. 

Jonathan Hemmerdinger can be reached at 791-6316 or:


Were you interviewed for this story? If so, please fill out our accuracy form

Send question/comment to the editors

Further Discussion

Here at we value our readers and are committed to growing our community by encouraging you to add to the discussion. To ensure conscientious dialogue we have implemented a strict no-bullying policy. To participate, you must follow our Terms of Use.

Questions about the article? Add them below and we’ll try to answer them or do a follow-up post as soon as we can. Technical problems? Email them to us with an exact description of the problem. Make sure to include:
  • Type of computer or mobile device your are using
  • Exact operating system and browser you are viewing the site on (TIP: You can easily determine your operating system here.)